Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin in Acute COPD Exacerbations
NCT02135354Phase 3Terminated
- Start
- Aug 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Azithromycin with Placebo (2 arms). Primary endpoint: Time to clinical failure at 90 days. Started Aug 2014; status: terminated.
02
Drugs
azithromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02135354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135354.